Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Neil Kelleher
Northwestern University, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Microbial Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Professor Kelleher is a founder of and has equity interests in Microbial Pharmaceutical. Microbial Pharmaceutical aims to create a pipeline to feed compounds from the natural world into pharmaceutical research. Microbial Pharmaceuticals has developed a platform, metabologenomics, that allows the study of the compounds that a class of bacteria produces rather than focusing on a single compound at a time. This NIH research involves biosynthetic studies focused on elucidating the biosynthesis of tambroline, a new amino acid that is part of the natural product, tambromycin. Tambromycin was discovered using technologies being commercialized by Microbial Pharmaceuticals. Professor Kelleher’s relationship with the company and his involvement in this Northwestern research presents a potential conflict of interest that should be managed.
Biosynthetic studies on an unusual amino acid monomer deriving the discovery of novel natural products through genome mining
Project Narrative Tambroline is a novel unique pyrrolidine-containing amino acid monomer found in the structure of the recently discovered actinobacterial metabolite tambromycin which appears to be essential for the detected anti-cancer activity of tambromycin, and therefore we aim to elucidate the steps involved in its biosynthesis. We also plan to identify the binding target of tambromycin through chemical proteomics. Additionally, we aim to search for novel secondary metabolites through genome mining led by a proposed biosynthetic cassette for pyrrolidine-containing monomers, towards the discovery of novel anticancer and/or antibacterial natural products comprising tambroline or tambroline-like substructures.
Filed on September 05, 2017.
Tell us what you know about Neil Kelleher's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Neil Kelleher”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Neil Kelleher | Northwestern University | Conflict of Interest | Microbial Pharmaceutical | Value cannot be readily determined |
| Neil Kelleher | Northwestern University | Conflict of Interest | Integrated Protein Technologies | Value cannot be readily determined |
| Neil Kelleher | Northwestern University | Conflict of Interest | ThermoFisher | $10,000 - $19,999 |
| Neil Kelleher | Northwestern University | Conflict of Interest | Microbial Pharmaceuticals | Value cannot be readily determined |
| Neil Kelleher | Northwestern University | Conflict of Interest | Proteinaceous | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.